Cite

HARVARD Citation

    Razvi, M. et al. (n.d.). Predictors of Vedolizumab Dose Escalation or Cessation in Inflammatory Bowel Disease Patients. American journal of gastroenterology. p. . [Online]. 
  
Back to record